Comparison of antiviral activitt between FeIFN-ω and FeIFN-α

Shengwu Gongcheng Xuebao/Chinese Journal of Biotechnology

Volumn 24, Issue 9, 2008, Pages 1556-1560

  Wa, Hongbin ^a,b   Jia, Xiaojuan ^b   Yang, Limin ^b   Sun, Lei ^b   Wang, Hongning ^c   Liu, Wenjun ^b  

^a SICHUAN AGRICULTURAL UNIVERSITY   (China)

^b INSTITUTE OF MICROBIOLOGY   (China)

^c SICHUAN UNIVERSITY   (China)

Author keywords

Antiviral activity; FeIFN ; FeIFN

Indexed keywords

AVIAN INFLUENZA VIRUS; CANINE DISTEMPER VIRUS; ESCHERICHIA COLI; FELIDAE;

ALPHA INTERFERON; ANTIVIRUS AGENT; INTERFERON; INTERFERON OMEGA 1;

ANIMAL; ARTICLE; BIOSYNTHESIS; CANINE DISTEMPER MORBILLIVIRUS; CAT; COMPARATIVE STUDY; DRUG EFFECT; GENETICS; INFLUENZA VIRUS A H9N2;

ANIMALS; ANTIVIRAL AGENTS; CATS; DISTEMPER VIRUS, CANINE; INFLUENZA A VIRUS, H9N2 SUBTYPE; INTERFERON TYPE I; INTERFERON-ALPHA;

EID: 75549086121     PISSN: 10003061     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (17)

1. De Maeyer E, De Maeyer-Guignard. Type I interferon. Intern Rev Immunol, 1998, 17: 53-73.
2. Walter MR, Bordens R, Nagabhushan TL, et al. Review of recent developments in the molecular characterization of recombinant alpHa interferons on the 40th anniversary of the discovery of interferon. Cancer Biother RadiopHarm, 1998, 13: 143-154.
3. Pfeffer LM, Dinarello CA, Herberman RB, et al. Biological properties of recombinant-interferons on the 40th anniversary of the discovery of interferon. Cancer Res, 1998, 58: 2489-2499.
4. Roberts MR, Cross JC, Leaman DW, et al. Unique features of the tropHoblast interferons. Pharm Ther, 1991, 51: 329-345.
5. Kenji Oritani, Paul W Kincade, Cai Zhang, et al. Type I interferons and limitin: a comparison of structures, receptors, and functions. Cytokine and Growth Factor Rev, 2001, 12: 337-348.
6. Yang LM, Xue QH, Sun L, et al. Cloning and characterization of a novel feline IFN-ω. Journal of Interferon & Cytokine Research, 2007, 27: 119-127.
7. De Mari K, Maynard L, Sanquer A, et al. Therapeutic effects of recombinant feline interferon-omega on feline leukemia virus (FeLV)-infected and FeLV/feline immunodeficiency virus (FIV)-coinfected symptomatic cats. Vet Intern Med, 2004, 18(4): 477-482.
8. Ishiwata K, Minagawa T, Kajimoto T. Clinical effects of the recombinant feline interferon-omega on experimental parvovirus infection in beagle dogs. Journal of Veterinary Medical Science, 1998, 60(8): 911-917.
9. Martin V, Najbar W, Gueguen S, et al. Treatment of canine parvoviral enteritis with interferon-omega in a placebo- controlled challenge trial. Veterinary Microbiology, 2002, 89(223): 115-127.
10. Zhang LX, Zhang TF, Wang JZ. The Protein Protocols Handbook. Beijing: Science Press, 2000, 8: 42-46.
11. John A, Armstrong. Semi-micro dye-binding assay for rabbit interferon. Applied Microbiology, 1971, 21(4): 723-725.
12. Sara Rubinstein, Philip C, Familletti, Sidney Pestka, et al. Convenient assay for interferons. Journal of Virology, 1981, 37(2): 755-758.
13. Fei ZZ, Guan YX, Yao SJ, et al. A colorimetric method to assay biological activity of recombinant human IFN-γ. Microbiology, 2001, 31(3): 65-69.
14. Enquist LW, Krug RM, Racaniello VR, et al. Principles of Virology: Molecular Biology, Pathogenesis, and Control (Hardcover). Washington DC: ASM Press, 2004, Chapter 2, 4, 42-58.
15. Pestka S, Langer JA, Zoon KC, et al. Interferons and their actions. Annu Rev Biochem, 1987, 56: 727-777.
16. Baron S, Coppenhaver DH, Dianzani F, Eds. Interferon. Principles and Medical Applications. Galveston, University of Texas, 1992, 1-15.
17. Kunzi MS, Pitha PM. Role of interferon-stimulated gene ISG215 in the interferon-omega-mediated inhibition of human immunodeficiency virus replication. Journal of Interferon & Cytokine Research, 1996, 16(11): 919-927.